Pertussis vaccination during pregnancy: Antibody persistence in infants
| Autor: | Marta López, Anna Goncé, Laia Ferrer, Josep Costa, Alba Vilajeliu, José M. Bayas, Jordina Munrós |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine Pediatrics medicine.medical_specialty Whooping Cough Embaràs 030106 microbiology Primary vaccination Diphtheria-Tetanus-acellular Pertussis Vaccines Infeccions respiratòries Persistence (computer science) Young Adult 03 medical and health sciences 0302 clinical medicine Pregnancy medicine Humans Pertussis vaccination Prospective Studies 030212 general & internal medicine General Veterinary General Immunology and Microbiology biology Tetanus business.industry Diphtheria Public Health Environmental and Occupational Health Infant Respiratory infections medicine.disease Antibodies Bacterial Infectious Diseases Immunoglobulin G biology.protein Molecular Medicine Gestation Female Antibody business Immunity Maternally-Acquired Half-Life |
| Zdroj: | Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2016.05.051 |
| Popis: | Maternal pertussis vaccination is associated with higher levels of pertussis antibodies at birth. We assessed the persistence of pertussis antibodies until primary vaccination in infants whose mothers received Tdap (tetanus, diphtheria, acellular pertussis) vaccine during pregnancy. Infants were born at the Hospital Clinic of Barcelona (Spain) in November 2014. Anti-PT IgG was determined by ELISA at delivery, between the first and second month of life, and estimated at 2months of age. The study included 37 infants whose mothers received Tdap between 21 and 38weeks of gestation. Infants presented a decline in GMC of anti-PT IgG between peripartum and follow-up levels, 52.7 (95% CI 34.7-80.2) versus 7.5 (95% CI 4.2-13.3) at 2months of age (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect